The article provides a comprehensive status report on global cancer incidence and mortality, based on the GLOBOCAN 2018 estimates from the International Agency for Research on Cancer (IARC). It highlights that in 2018, there will be an estimated 18.1 million new cancer cases (excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (excluding nonmelanoma skin cancer). Lung cancer is the most common cancer and the leading cause of cancer death, followed by breast cancer, prostate cancer, and colorectal cancer. The distribution of cancer cases and deaths varies significantly across regions, with Asia accounting for nearly half of all cases and over half of all deaths. The article also discusses the impact of socioeconomic development on cancer incidence and mortality, noting that high-quality cancer registry data are crucial for planning and implementing effective cancer control programs. The Global Initiative for Cancer Registry Development is highlighted as a key international partnership supporting better estimation and collection of local data. The article concludes by emphasizing the need for population-based national and subnational cancer surveillance data to improve the accuracy of GLOBOCAN estimates and inform on-the-ground cancer control initiatives.The article provides a comprehensive status report on global cancer incidence and mortality, based on the GLOBOCAN 2018 estimates from the International Agency for Research on Cancer (IARC). It highlights that in 2018, there will be an estimated 18.1 million new cancer cases (excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (excluding nonmelanoma skin cancer). Lung cancer is the most common cancer and the leading cause of cancer death, followed by breast cancer, prostate cancer, and colorectal cancer. The distribution of cancer cases and deaths varies significantly across regions, with Asia accounting for nearly half of all cases and over half of all deaths. The article also discusses the impact of socioeconomic development on cancer incidence and mortality, noting that high-quality cancer registry data are crucial for planning and implementing effective cancer control programs. The Global Initiative for Cancer Registry Development is highlighted as a key international partnership supporting better estimation and collection of local data. The article concludes by emphasizing the need for population-based national and subnational cancer surveillance data to improve the accuracy of GLOBOCAN estimates and inform on-the-ground cancer control initiatives.